COVID-19 REGISTRY [COVID-19]
Research type
Research Study
Full title
Registry to study factors that may impact COVID-19 occurrence and severity
IRAS ID
284169
Contact name
Nancy Dreyer
Contact email
Clinicaltrials.gov Identifier
NCT04368065, www.ClinicalTrials.gov
Duration of Study in the UK
0 years, 7 months, 20 days
Research summary
This registry will enroll participants in an observational, direct-to-participant longitudinal study to assess disease risk, progression, and treatments.\nThe 2019 coronavirus disease (COVID-19) has presented major challenges to countries around the world. Currently there is little information about (1) symptom prevalence and severity, especially for less severe cases, (2) how to characterize those at highest risk, including the role of ibuprofen and various hypertension and anti-diabetic medications, (3) whether vitamin and mineral supplements as well as prescription and non-prescription medications infer any degree of protection, and (4) what medical management is most effective at reducing the toll of this infection. \nThe objective of this study is to identify factors that may impact the occurrence or severity of COVID-19 infections including examining the role of underlying health conditions, prescription and over-the-counter medications, vitamins and supplements. \nParticipants will be recruited through postings from partner organizations such as governments and professional associations as well as support from advertising, social media, and public relations.People with potential exposure to COVID-19 will be asked to visit the online study portal and to complete an initial baseline survey.The study follow-up period is 3 months. Since the COVID-19 situation is rapidly evolving, with new evidence discovered daily, the science team may extend the follow-up period to up to 6 months if we feel that findings support continuing the observational period further.\nNo medical advice will be provided; links to government sites and other credible medical resources about COVID-19 will be made available.\nDetailed information of the study will be provided to patients and those who voluntarily agree for their data to be collected and analysed, in accordance with local requirements, will sign an informed consent form (ICF) before any study-related activity. Patient’s personal information will be kept completely private, no matter which county it goes to, even if that country does not have the same level of protection for personal information as in the UK.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
20/SC/0242
Date of REC Opinion
28 May 2020
REC opinion
Favourable Opinion